Curcuminoids and Contrast-induced Acute Kidney Injury

Bangkok Metropolitan Administration Medical College and Vajira Hospital

Status and phase: Completed; Early Phase 1

Conditions: Chronic Kidney Diseases; Curcuminoid; Acute Kidney Injury; Contrast Media Toxicity

Treatments: Drug: Curcuminoid; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04890704

157/61

Details and patient eligibility

About

The objective of this study was to evaluate the role of curcuminoids in the prevention of CI-AKI in CKD patients.The result of the study was prophylactic administration with curcuminoids in addition to standard treatment reduce the incidence of CI-AKI CKD patients undergoing elective CAG.

Full description

This study was a single-center, prospective, double-blinded, randomized placebo-controlled trial in CKD patients undergoing elective coronary angiography (CAG) at Vajira hospital from October 2018 to March 2019. Patients were stratified according to baseline estimate glomerular filtration rate (eGFR) and diabetes status. They were randomized to Curcuminoids 1,500 milligrams per day starting 3 days before and 2 days after coronary procedure or placebo. The primary outcome was the development of CI-AKI, defined as serum creatinine rising ≥ 0.3 mg/dL within 48 hours after coronary angiography. The secondary outcomes were overall AKI incidences within 7 days after CAG, changes in eGFR, IL-6 hs-CRP, and other adverse events.

A total of 60 patients were enrolled( 30 in curcuminoids group, and 30 in the control group). Overall AKI developed in 5 patients in control group and none in curcuminoids group (16.67% versus 0%, p-value 0.052). The results showed that curcuminoids could preserve changes in eGFR compared to the placebo group (-1.5 vs 2.5 mL/min/1.73m2, p-value <0.001 within 48 hours and -4 versus 1 mL/min/1.73m2, p-value 0.002 within 7 days). The high-sensitive C-reactive protein (hs-CRP) and IL-6 levels were not different between patients receiving curcuminoids and placebo. In curcuminoids group, 3 patients developed mild nausea and diarrhea that improved with supportive care. No serious adverse events were found in both groups.

Enrollment: 96 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All the patients undergoing elective CAG at Vajira hospital from October 2018 to March 2019 were included in the study
• older than 18 years old
• stable eGFR 15-60 mL/min/1.73m2 in last 3 months.

Exclusion criteria

• dialysis-dependent
• post-kidney transplantation
• acute heart failure or critically ill
• history of contrast or turmeric allergy
• increasing of alanine aminotransferase (ALT) or alkaline phosphatase (ALP) more than three times of normal upper limits or post-cholecystectomy
• history of AKI (as evidence by sCr change ≥ 0.3 mg/dL) within 14 days before the study - using medication included NSAIDs, warfarin, immunosuppression, N-acetyl cysteine, ascorbic acid or contrast agents within 14 days before the study
• pregnancy or lactation o
• denied consent .

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

96 participants in 2 patient groups, including a placebo group

Curcumioids

Experimental group

Description:

The investogators prescribed curcuminoids 1,500 mg/day . The regimen was curcuminoids 500 mg three times a day from three days before the procedure until two days after. All patients also received standard prophylaxis protocol which included 0.9% sodium chloride 1 mL/kg/hour, given 12 hours before and 12 hours after CAG unless contraindicated.

Treatment:

Drug: Curcuminoid

Placebo

Placebo Comparator group

Description:

The placebo was identical capsule given three times daily and the remaining protocols were the same as the active group

Treatment:

Drug: Placebo